tetano
Editor, Senior Moderator
Sci Rep
. 2026 Jan 19.
doi: 10.1038/s41598-026-35878-8. Online ahead of print.
Variations in the perceived value of anti-SARS-CoV-2 therapeutics based on physicians' clinical backgrounds
Akihiko Hagiwara[SUP] #[/SUP][SUP] 1 [/SUP], Kosaku Komiya[SUP] #[/SUP][SUP] 2 [/SUP], Yuichiro Shindo[SUP] 3 [/SUP], Kazufumi Takamatsu[SUP] 4 [/SUP], Naoki Nishimura[SUP] 5 [/SUP], Yukako Takechi[SUP] 6 [/SUP], Eiki Ichihara[SUP] 7 [/SUP], Takahiro Takazono[SUP] 8 [/SUP], Shinyu Izumi[SUP] 5 [/SUP], Shimpei Gotoh[SUP] 9 [/SUP], Seiichiro Sakao[SUP] 10 [/SUP], Takehiro Izumo[SUP] 11 [/SUP], Kazuko Yamamoto[SUP] 12 [/SUP], Kazuhiro Yatera[SUP] 13 [/SUP], Hiroshi Kakeya[SUP] 14 [/SUP], Yoko Shibata[SUP] 15 [/SUP], Keisuke Tomii[SUP] 16 [/SUP], Hironori Sagara[SUP] 17 [/SUP], Yuka Sasaki[SUP] 18 [/SUP], Toyohiro Hirai[SUP] 19 [/SUP], Akihito Yokoyama[SUP] 4 [/SUP], Hiroshi Mukae[SUP] 8 [/SUP], Takashi Ogura[SUP] 20 [/SUP]
Affiliations
Although the global emergency phase of the coronavirus disease 2019 (COVID-19) pandemic has ended, antiviral therapy remains crucial for patients at high risk of severe illness. In Japan, the out-of-pocket costs for antiviral drugs shifted from full public coverage to partial patient payment in April 2024. However, the impact of physicians' background characteristics on antiviral cost perceptions and prescribing behavior remains underexplored. This study involved a secondary analysis of a nationwide, web-based interventional survey of 1,500 physicians treating COVID-19. Participants reported whether they avoided prescribing antivirals owing to drug costs and identified what they considered an appropriate cost per treatment course. Associations between physicians' characteristics and their cost perceptions were analyzed. Among 1,500 physicians surveyed, 1,193 (79.5%) reported avoiding antiviral prescriptions owing to drug costs. The most commonly selected appropriate cost was ≤ 33 USD (65.0%). Generalists, pulmonologists, ear, nose, and throat specialists, and clinic-based physicians were more likely to refrain from prescribing antivirals and favor lower treatment costs compared with physicians in other specialties or hospital settings. A multivariate analysis revealed workplace setting as the only factor independently associated with cost-related prescribing behavior. High antiviral drug costs in Japan may contribute to underprescription, particularly among clinic-based physicians, and this underprescription could hypothetically lead to delays in treatment, which might increase the risk of severe outcomes in high-risk patients. As high-risk patients with mild COVID-19 often first seek care in clinics, promoting appropriate antiviral use in these settings is essential. Strengthening communication and sharing clinical experiences between hospitals and clinics may help reduce prescribing disparities driven by drug costs.
Keywords: Antiviral; COVID-19; Prescription; Workplace.
. 2026 Jan 19.
doi: 10.1038/s41598-026-35878-8. Online ahead of print.
Variations in the perceived value of anti-SARS-CoV-2 therapeutics based on physicians' clinical backgrounds
Akihiko Hagiwara[SUP] #[/SUP][SUP] 1 [/SUP], Kosaku Komiya[SUP] #[/SUP][SUP] 2 [/SUP], Yuichiro Shindo[SUP] 3 [/SUP], Kazufumi Takamatsu[SUP] 4 [/SUP], Naoki Nishimura[SUP] 5 [/SUP], Yukako Takechi[SUP] 6 [/SUP], Eiki Ichihara[SUP] 7 [/SUP], Takahiro Takazono[SUP] 8 [/SUP], Shinyu Izumi[SUP] 5 [/SUP], Shimpei Gotoh[SUP] 9 [/SUP], Seiichiro Sakao[SUP] 10 [/SUP], Takehiro Izumo[SUP] 11 [/SUP], Kazuko Yamamoto[SUP] 12 [/SUP], Kazuhiro Yatera[SUP] 13 [/SUP], Hiroshi Kakeya[SUP] 14 [/SUP], Yoko Shibata[SUP] 15 [/SUP], Keisuke Tomii[SUP] 16 [/SUP], Hironori Sagara[SUP] 17 [/SUP], Yuka Sasaki[SUP] 18 [/SUP], Toyohiro Hirai[SUP] 19 [/SUP], Akihito Yokoyama[SUP] 4 [/SUP], Hiroshi Mukae[SUP] 8 [/SUP], Takashi Ogura[SUP] 20 [/SUP]
Affiliations
- PMID: 41554856
- DOI: 10.1038/s41598-026-35878-8
Although the global emergency phase of the coronavirus disease 2019 (COVID-19) pandemic has ended, antiviral therapy remains crucial for patients at high risk of severe illness. In Japan, the out-of-pocket costs for antiviral drugs shifted from full public coverage to partial patient payment in April 2024. However, the impact of physicians' background characteristics on antiviral cost perceptions and prescribing behavior remains underexplored. This study involved a secondary analysis of a nationwide, web-based interventional survey of 1,500 physicians treating COVID-19. Participants reported whether they avoided prescribing antivirals owing to drug costs and identified what they considered an appropriate cost per treatment course. Associations between physicians' characteristics and their cost perceptions were analyzed. Among 1,500 physicians surveyed, 1,193 (79.5%) reported avoiding antiviral prescriptions owing to drug costs. The most commonly selected appropriate cost was ≤ 33 USD (65.0%). Generalists, pulmonologists, ear, nose, and throat specialists, and clinic-based physicians were more likely to refrain from prescribing antivirals and favor lower treatment costs compared with physicians in other specialties or hospital settings. A multivariate analysis revealed workplace setting as the only factor independently associated with cost-related prescribing behavior. High antiviral drug costs in Japan may contribute to underprescription, particularly among clinic-based physicians, and this underprescription could hypothetically lead to delays in treatment, which might increase the risk of severe outcomes in high-risk patients. As high-risk patients with mild COVID-19 often first seek care in clinics, promoting appropriate antiviral use in these settings is essential. Strengthening communication and sharing clinical experiences between hospitals and clinics may help reduce prescribing disparities driven by drug costs.
Keywords: Antiviral; COVID-19; Prescription; Workplace.